Cytora, a clinical stage company developing unique stem cell treatments based on human Oral Mucosa Stem Cells (hOMSCs), reported today successful results of a Phase 1/2a clinical trial for treating ...

Diabetic foot infections can lead to severe complications, including amputation, which carries a high mortality rate. The promising results of BX211 suggest potential benefits in ulcer healing ...

thus enabling the production of an "off the shelf" stem cell treatment platform for human use. About Diabetic Foot Ulcers Diabetic foot ulcers (DFUs) are open sores or wounds that occur in ...

FibroBiologics and Charles River have announced the completion of FibroBiologics’ master cell bank for a product that will be evaluated for the treatment of diabetic foot ulcers and other ...

FBLG READ THE FULL FBLG RESEARCH REPORT Business Update Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 ...

More New Mexicans will be able to receive treatment for diabetic foot ulcers, thanks to a first-in-the-nation requirement for some health insurance plans to cover the costs. Gov. Michelle Lujan ...

Diabetic foot infections can lead to severe complications, including amputation, which carries a high mortality rate. The promising results of BX211 suggest potential benefits in ulcer healing ... to ...

BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at ...

Phase 1/2 Trial in Diabetic Foot Ulcers to Initiate in 2Q25 FibroBiologics ... the planned Phase 1/2 clinical trial of CYWC628 for the treatment of DFUs. CYWC628 is being developed for the ...

Celularity (CELU) welcomes action by the Centers for Medicare & Medicaid Services, or CMS, to revise to January 1, 2026, the effective date ...